AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 271 min read$IRON

Yu Jonathan Yen-Wen sold $756K of IRON

Yu Jonathan Yen-Wen (Chief Operating Officer) sold 9,096 shares of Disc Medicine, Inc. (IRON) at an average of $83.10 ($82.53–$83.12, $0.76M total) across 2 trades over 2026-08-24 to 2026-08-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Yu Jonathan Yen-Wen
Published Aug 27, 2026, 12:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 1:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IRON
Neutral
medium confidence
Mentioned
$IRON
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRONNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly, but may attract short interest.

02

Market read

Routine insider sale with limited market impact.

03

What to watch

COO may be diversifying personal portfolio; no change in company fundamentals.

Relevance 4/10Novelty 4/10Timing: filed after market close on 2026-08-26

Background

Form 4 filing discloses insider transactions required by SEC; provides transparency on insider holdings.

Company-level read

Ticker impact

$IRONNeutralMedium confidence
Context

COO Yu Jonathan Yen-Wen sold 9,096 shares for $756K via a 10b5-1 plan, reducing his stake to 54,324 shares.

Expected impact

Potential short-term downward pressure, limited impact due to low volume.

Evidence & confidence

Sale amount is under $1M and represents a small percentage of total shares; market may view as routine.

Market effects

Sector

Minimal effect on biotech sector; insider sales are common.

Regional

None

Global

None

Counterpoint

What could challenge this read

Sale could be a strategic reallocation rather than lack of confidence.

Key entities

  • Company
    Disc Medicine, Inc.

    Biotech firm focused on drug development.

  • Insider
    Yu Jonathan Yen-Wen

    Chief Operating Officer of Disc Medicine.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IRON insider trading history →

Related articles

SEP 11
$JNJMedAI 8/10

Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials

Johnson & Johnson (JNJ) received CE Marking for ACUVUE OASYS MAX 2-Week contact lenses. GSK (GSK) expanded Shingrix approval in Japan. Axogen (AXGN) to acquire BioCircuit for $200M. Femasys (FEMY) partnered with CapexMD for fertility financing. EpilepsyGTx collaborated with Viralgen (BAYN.DE) for gene therapy. HCW Biologics (HCWB) partnered with Akron Biotech. Bluejay Diagnostics (BJDX) teamed with Lovell for federal market access. Transgene (TNG.PA) expanded partnership with ProBioGen. Oncolyti

rttnews.com3 min
JUL 17
$NEEMed

SMALL-CAP MOVERS: Britain's bargain basement and the overseas buyers who can't believe their luck

The article reports AIM takeover activity: Gooch & Housego PLC is being acquired in a £346m deal, and Ramsdens Holdings PLC is set to be bought for £230m. It also notes NextEnergy Solar rose 10% after putting itself up for sale, and highlights large AIM share moves for Ironveld, Itaconix, Jersey Oil and Gas, Safestay, Galileo Resources, and Iofina. Iofina reported 393.3 tonnes H1 2026 and raised guidance to 460-485 tonnes.

proactiveinvestors.co.uk7 min
JUL 14
$IRONMed

Ironveld shares jump 32% at 0.025p as processing plant hits sustained production

Ironveld PLC (AIM:IRON) shares rose 32% to 0.025p after the company said its dense media separation plant reached sustained production. It now runs 16 hours daily on double shift, processing 2.5-3.5 tonnes per hour and producing 1.4 tonnes/hour in-spec magnetite plus about 1 tonne/hour maghemite. Three clients secured, with a 5,000 tonnes/month buyer sampling; expansion options and Mintek study ongoing.

proactiveinvestors.co.uk3 min
JUN 12
$IRONMed

Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting

Disc Medicine (NASDAQ:IRON) reported updated clinical data at the 2026 EHA meeting in Stockholm. In RALLY-MF, DISC-0974 showed durable overall anemia responses in myelofibrosis across subgroups, including 55% major hemoglobin response in non-transfusion dependent patients and transfusion independence in 64% (TD Low) and 50% (TD High). In HELIOS, bitopertin sustained PPIX reductions and improved light tolerance with favorable longer-term safety. A corporate call is set for June 15.

manilatimes.net4 min
JUN 4
$IRONLow

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

Rosen Law Firm said it is investigating potential securities claims for Disc Medicine, Inc. (NASDAQ: IRON) shareholders, alleging materially misleading business information. The firm cited an FDA Complete Response Letter on Feb. 13, 2026 for Disc Medicine’s bitopertin NDA, citing uncertainties needing more evidence; IRON shares fell 22% that day.

prnewswire.com2 min